Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.
Clinical trial NCT05803395 · UNKNOWN
Trial details
- NCT number
- NCT05803395
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2023-09-12
- Primary completion
- 2024-09-01
- Enrollment
- 954
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.